We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Polar Capital Global Healthcare Trust plc (PCGH) Ordinary 25p Shares

Sell:369.00p Buy:373.00p 0 Change: 2.00p (0.54%)
Market closed Prices as at close on 20 May 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Change: 2.00p (0.54%)
Market closed Prices as at close on 20 May 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Change: 2.00p (0.54%)
Market closed Prices as at close on 20 May 2024 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.


The Company’s investment objective is to generate capital growth by investing in a global portfolio of healthcare stocks.The Company seeks to achieve this objective by investing in a diversified global portfolio consisting primarily of listed equities issued by healthcare companies involved in pharmaceuticals, medical services, medical devices and biotechnology. The portfolio is expected to be diversified by factors such as geography, industry sub-sector and investment size.
Security Weight
Eli Lilly and Co 8.50%
UnitedHealth Group Inc 6.34%
Zealand Pharma AS DKK1 5.64%
AbbVie Inc 5.62%
Intuitive Surgical Inc 4.73%
Novartis AG CHF50 4.48%
Ucb SA NPV (CDI) 4.06%
Sanofi Ordinary Euro 2 3.87%
Elevance Health Inc 3.63%
Becton Dickinson & Co 3.55%
Sector Weight
Healthcare 106.53%
Consumer Defensive 1.73%
Country Weight
United States 60.20%
Switzerland 10.90%
Denmark 7.74%
France 7.03%
United Kingdom 5.72%
Japan 4.64%
Belgium 4.06%
Australia 3.03%
Sweden 2.97%
India 1.30%

Fee Structure

Management fee is 0.75% p.a. of the lower of the Market Capitalisation and NAV. Performance fee is equal to 10% of the excess total return over benchmark Index plus 1.5% p.a. compounded annually. Agreement terminable not less than 12 months written notice.

Dividend Policy

The Company focus remains on capital growth, and the dividend will be paid bi-annually in February and August. The policy may result in lower dividends being paid than historically to recognise the focus on capital growth.


Total number of holdings: 41.

Trust Manager

James Douglas

Manager Bio

James joined Polar Capital in September 2015 and is a Fund Manager for the Healthcare team. He was appointed Co-Fund Manager for the Polar Capital Global Healthcare Trust in May 2017.Prior to joining Polar Capital, James worked in equity sales specialising in global healthcare at Morgan Stanley, RBS and HSBC. James also has equity research experience garnered from his time at UBS, where he worked as an analyst in the European pharmaceutical and biotechnology team. Before moving across to the financial sector, he worked as a consultant for EvaluatePharma. James received a PhD and first class honours degree in Medicinal Chemistry from Newcastle University. Further to this, James also holds an ACCA diploma in financial management.

Board Of Directors

Lisa ArnoldChairman, Jeremy Whitley, Andrew Fleming, Neal Ransome

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Objective, holding data, trust manager and bio information, dividend policy, asset split and fee structure are provided by Morningstar.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.